These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 29202535

  • 1. [The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis].
    Ma H, Sun F, Zhang YM, Zhang H, Zhu J, Deng XH, Zhang JL, Huang F.
    Zhonghua Nei Ke Za Zhi; 2017 Dec 01; 56(12):935-939. PubMed ID: 29202535
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, Hsia EC.
    Rheumatology (Oxford); 2014 Sep 01; 53(9):1654-63. PubMed ID: 24729398
    [Abstract] [Full Text] [Related]

  • 3. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
    Reveille JD, Deodhar A, Caldron PH, Dudek A, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.
    J Rheumatol; 2019 Oct 01; 46(10):1277-1283. PubMed ID: 30824635
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
    Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, Berd Y, Bergman G, Curtis S, Tzontcheva A, Huyck S, Weng HH.
    Arthritis Rheumatol; 2015 Oct 01; 67(10):2702-12. PubMed ID: 26139307
    [Abstract] [Full Text] [Related]

  • 5. Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.
    Deodhar A, Reveille JD, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.
    J Rheumatol; 2018 Mar 01; 45(3):341-348. PubMed ID: 29247154
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B.
    Arthritis Res Ther; 2017 Dec 22; 19(1):285. PubMed ID: 29273067
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
    Inman RD, Davis JC, Heijde Dv, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J.
    Arthritis Rheum; 2008 Nov 22; 58(11):3402-12. PubMed ID: 18975305
    [Abstract] [Full Text] [Related]

  • 8. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.
    Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, Han C, Hsu B.
    Ann Rheum Dis; 2015 Apr 22; 74(4):757-61. PubMed ID: 25387477
    [Abstract] [Full Text] [Related]

  • 9. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.
    Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, Hsu B.
    Ann Rheum Dis; 2012 May 22; 71(5):661-7. PubMed ID: 22012970
    [Abstract] [Full Text] [Related]

  • 10. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial.
    Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, Hsu B, Gathany T, van der Heijde D.
    Arthritis Care Res (Hoboken); 2010 Sep 22; 62(9):1266-71. PubMed ID: 20506403
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
    Arthritis Rheum; 2005 Feb 22; 52(2):582-91. PubMed ID: 15692973
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, ATLAS Study Group.
    Arthritis Rheum; 2006 Jul 22; 54(7):2136-46. PubMed ID: 16802350
    [Abstract] [Full Text] [Related]

  • 13. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V, Plosker GL.
    BioDrugs; 2009 Jul 22; 23(2):125-35. PubMed ID: 19489653
    [Abstract] [Full Text] [Related]

  • 14. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A.
    Arthritis Rheum; 2009 Apr 22; 60(4):976-86. PubMed ID: 19333944
    [Abstract] [Full Text] [Related]

  • 15. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
    van der Heijde D, Pangan AL, Schiff MH, Braun J, Borofsky M, Torre J, Davis JC, Wong RL, Kupper H, Collantes E, ATLAS Study Group.
    Ann Rheum Dis; 2008 Sep 22; 67(9):1218-21. PubMed ID: 18056755
    [Abstract] [Full Text] [Related]

  • 16. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J.
    Arthritis Rheum; 2010 May 22; 62(5):1290-7. PubMed ID: 20461780
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.
    Int J Rheum Dis; 2016 Nov 22; 19(11):1143-1156. PubMed ID: 26259617
    [Abstract] [Full Text] [Related]

  • 18. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
    Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ.
    Ann Rheum Dis; 2018 Sep 22; 77(9):1295-1302. PubMed ID: 29945918
    [Abstract] [Full Text] [Related]

  • 19. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial.
    Tam LS, Shang Q, Kun EW, Lee KL, Yip ML, Li M, Li TK, Zhu TY, Pui MO, Li EK, Yu CM.
    Rheumatology (Oxford); 2014 Jun 22; 53(6):1065-74. PubMed ID: 24501241
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
    Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R, Porter B.
    Int J Rheum Dis; 2017 May 22; 20(5):589-596. PubMed ID: 28544533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.